Niagen Bioscience increases share repurchase program to $20M
Source: SeekingAlpha
2026-03-19 08:41:02 ET
More on Niagen Bioscience
- Niagen Bioscience: Why Discipline Matters In A Crowded Supplement Market
- Niagen Bioscience targets 10–15% revenue growth for 2026 while expanding injectable product line
- Niagen Bioscience GAAP EPS of $0.05 beats by $0.03, revenue of $33.84M beats by $2.14M
Read the full article on Seeking Alpha
For further details see:
Niagen Bioscience increases share repurchase program to $20M
Niagen Bioscience Inc.
NASDAQ: NAGE
NAGE Trading
2.75% G/L:
$3.365 Last:
472,919 Volume:
$3.31 Open:
NAGE Latest News
April 10, 2026 09:00:00 am
The $120 Billion Longevity Economy Is Shifting From Supplements to Therapies That Target Aging Itself - And One Small-Cap Is Producing An Anti-Aging Protein From Encapsulated Cells
April 09, 2026 08:32:00 am
Niagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen®
$408,607,432
52,743,877
N/A
66
N/A
Biotechnology & Life Sciences
Healthcare
US
Los Angeles
